glp 1 not fda approved Dissing Disinformation Shed GLP-1 Review 2026 Explores

Exenatide and lixisenatide both have relatively short half-lives and are considered short-acting GLP-1 RAs

With spending projections expecting continued sharp increases, PBMs have an important role to play in shaping prescription patterns more aligned with medical evidence (including trial data, treatment guidelines, medical best practices, etc.) and comparative research rather than drug maker promotional agendas

The Congressional Budget Office (CBO) estimates that Medicare coverage alone would increase net federal spending by roughly $36 billion by 2034

Another study a meta-analysis and review of 78 trials involving more than 73,000 participants concluded that semaglutide was associated with an increased incidence of NAION but emphasized that evidence for a causal link remains inconclusive

[DOI] [PMC free article] [PubMed] [Google Scholar] 51.Herman R.J., Hayes M.R., Audrain-McGovern J., Ashare R.L., Schmidt H.D